Skip to content
Biodatica
Start free

ENZYCHEM LIFESCIENCES CORPORATION

Location not on file

OncologyFiled/Approved
Compare Sign in to watch

What changed

NIH R01 · $0.5M · Autophagy in liver injury

5mo agoGrant renewalJan 27, 2026Source filing (opens the source filing in a new tab)

Momentum

68no change

Momentum 68 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

56 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Sep 23, 2025

    Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor · NOT_YET_RECRUITING · sponsor: Kim's Eye Hospital · Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

    ClinicalTrials.gov · NCT07187804 (opens the source filing in a new tab)

  2. Patent

    Patent granted

    Jan 7, 2025

    assignee: ENZYCHEM LIFESCIENCES CORPORATION · 1,2-DIACYLGLYCEROL COMPOUND, PREPARATION METHOD THEREFOR, AND IMMUNOMODULATOR CONTAINING SAME AS ACTIVE INGREDIENT

    USPTO · US 12187672 (opens the source filing in a new tab)

  3. Trial

    PHASE4 registered

    Dec 26, 2022

    Pachychoroid Neovasculopathy · COMPLETED · sponsor: Kim's Eye Hospital · Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

    ClinicalTrials.gov · NCT05662410 (opens the source filing in a new tab)

  4. Patent

    Patent assigned

    Sep 8, 2020

    assignee: ENZYCHEM LIFESCIENCES CORPORATION · 1,2-DIACYLGLYCEROL COMPOUND, PREPARATION METHOD THEREFOR, AND IMMUNOMODULATOR CONTAINING SAME AS ACTIVE INGREDIENT

    USPTO · US 12187672 (opens the source filing in a new tab)

  5. Trial

    NA registered

    Jan 21, 2020

    Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma · ACTIVE_NOT_RECRUITING · sponsor: City of Hope Medical Center · Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

    ClinicalTrials.gov · NCT05203627 (opens the source filing in a new tab)

  6. Grant

    R01 · $456k · non-dilutive

    Mar 5, 2009

    WASHINGTON UNIVERSITY · PI KIM, JAE-SUNG · NIDDK · award ends Jan 31, 2027 · Autophagy in liver injury

    NIH RePORTER · NIH RePORTER 11290349 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources